Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

37 results about "ATOPICLAIR" patented technology

Canine atopic dermatitis animal model of and use thereof

PCT designated stage expiredWO2025116616A1Peptide/protein ingredientsPharmaceutical delivery mechanismEpicutaneous sensitizationClinical research
The present invention relates to a method for producing a canine atopic dermatitis animal model, a canine atopic dermatitis animal model produced thereby, and a use thereof. According to the present invention, a canine atopic dermatitis animal model is produced by skin stimulation on a dog through epicutaneous sensitization with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 1 to 2 weeks and then with ovalbumin at a concentration of 1 to 5 mg / ml once daily for 2 to 8 weeks. The resulting animal model exhibits clinical symptoms of atopic dermatitis, changes in relevant factors such as increased expression levels of IgE and CCL17, and elevated expression levels of Th2-related cytokines IL-4, IL-31, and IL-13. Therefore, this invention enables the establishment of a standardized animal model for symptoms and Th2 immune responses appearing upon the onset of atopic dermatitis, and the model can be used in clinical studies for screening candidate agents for the prevention, alleviation, or treatment of atopic dermatitis.
Owner:KOREA RES INST OF CHEM TECH

Skin moisturizing external compositions

The present invention relates to skin moisturizing external compositions containing a ceramide, a cholesterol, and a fatty acid, and more particularly, to skin moisturizing external compositions capable of preventing skin troubles such as atopy by forming a dense lamellar structure, which is an intercellular lipid structure, and improving the skin barrier, and may include a ceramide having long-chain fatty acids, a cholesterol, a long-chain fatty acid, and purified water as active ingredients.
Owner:JIN HONGJONG

Novel nitrogen-containing heterocyclic compounds

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
Owner:PFIZER INC

Methods of Detecting and Preventing Atopic Allergic Diseases

The present invention is related to novel methods for identifying a population of subjects that are at risk for developing of atopic allergic diseases, and to the prevention of these allergic diseases.
Owner:SAMSUNG LIFE PUBLIC WELFARE FOUND +1

Maqui berry extracts for treatment of skin diseases

The present invention relates generally to maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient. Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, age spot, freckles and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing said skin diseases or defects.
Owner:ANKLAM EXTRAKT GMBH

Paste composition, biodegradable injectable paste, and method for producing same

The present invention relates to a paste composition, a biodegradable injectable paste, and a method for producing the same. According to the present invention, the paste composition may offer the convenience of being applied to the application site using one syringe without the need to mix using two syringes immediately before use, by providing a crosslinked hydrogel as a paste phase, as well as biocompatibility, tackiness, and the balance between viscosity and elasticity, and thus is suitable for use in applications, including hemostatic agents, bone fillers, wound dressings, drug carriers, tissue repair materials, skin soothing agents, moisturizing agents, anti-inflammatory agents, and anti-atopic agents.
Owner:GENEWEL CO LTD

Nitrogen-Containing Heterocyclic Compounds

The disclosure relates to compounds of the disclosure and pharmaceutically acceptable salts thereof to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of disease(s) such as atopic dermatitis, eosinophilic gastritis, atopic keratoconjunctivitis, allergy, alopecia, Alzheimer's disease, asthma, atherosclerosis, Bechet's disease, bullous pemphigoid, cancer, chronic obstructive pulmonary disease, chronic pruritis, chronic urticaria, Crohn's disease (CD), dermatitis, diabetic kidney disease, eosinophilic esophagitis, fungal keratitis, gout, idiopathic pulmonary fibrosis (IPF), keloids, non-alcoholic steatohepatitis (NASH), primary biliary cirrhosis, prurigo nodularis, psoriasis, psoriatic arthritis, rhinosinusitis, scleroderma, systemic lupus erythematosus (SLE), systemic sclerosis, ulcerative colitis (UC), vitiligo, or hidradenitis suppurativa. The compounds of the disclosure may be useful in the treatment, prevention, suppression and amelioration of a dermatological condition or a respiratory condition.
Owner:PFIZER INC

Composition and kit for preventing or treating atopic eczema and application thereof

In some embodiments, a composition comprising an effective amount of Bifidobacterium breve, Bifidobacterium bifidum, and Lactobacillus salivarius is provided. In some embodiments, the use of the composition in the prevention or treatment of atopic eczema in a subject is provided. In some embodiments, there is provided a method of preventing or treating atopic eczema in a subject, the method comprising the step of administering to the subject an effective amount of the composition. In some embodiments, there is provided a kit comprising: a composition of any one of the examples herein; and at least one container selected from the group consisting of capsules, pouches, packets, sachets, bottles, and blister packages. Other exemplary embodiments are described herein. In certain embodiments, the compositions are safe to use and effective to prevent or treat atopic eczema in a subject, especially an adult subject.
Owner:MICROBIOTA I CENT MAGIC LTD

Application of sodium hyaluronate in preparation of external medicine for treating allergic rhinitis

The invention relates to the field of allergic rhinitis, and discloses an application of sodium hyaluronate in preparation of an external medicine for treating allergic rhinitis. Based on actual clinical efficacy verification, the mechanism of sodium hyaluronate playing efficacy is that sodium hyaluronate can be used for preparing an external medicine for treating allergic rhinitis; sodium hyaluronate is used for reducing drainage lymph nodes in an atopic individual area and generating specificity I gE by nasal submucosa plasma cells, blocking contact between allergens and the surface specificity I gE of sensitized mast cells or sensitized basophilic granulocytes in a sensitized body, stopping development of anaphylaxis and promoting subduing of nasal mucosa inflammation, so that allergy symptoms are eliminated, and the nasal mucosa inflammation eliminating effect is achieved. According to the embodiment of the invention, the result of treating AR by adopting HA nasal drops shows that an obvious effect is achieved 1-2 days after the medicine is taken, the medicine takes effect quickly, the safety is relatively high, and the medicine can be used as a new product for industrial reproducible production.
Owner:屈军校

Composition for preventing and treating atopy comprising stichopus japonicus-derived extracellular vesicles

The present invention relates to a composition for treating atopic dermatitis, the composition comprising Stichopus japonicus-derived extracellular vesicles. Treating LPS-induced inflammation macrophages and mouse models with Stichopus japonicus-derived extracellular vesicles was found to activate anti-inflammatory effects. Accordingly, the composition comprising Stichopus japonicus-derived extracellular vesicles has an excellent therapeutic effect on atopic dermatitis and can be utilized in the field of researching better therapeutic effects, and thus can be used in useful businesses related to atopic dermatitis.
Owner:GLOPEX CO LTD

Stable liquid antibody formulation for dupilumab

The present invention relates to a liquid antibody formulation comprising an antibody, preferably dupilumab, L-arginine at a concentration of from 150 to 300 mM, a surfactant, and optionally a buffer, wherein the pH of the liquid antibody formulation is from 5.0 to 7.0. The invention further relates to a method for the preparation thereof and use of the liquid antibody formulation in the treatment, prevention or amelioration of any disease or disorder associated with IL-4 activity, including diseases or disorders mediated by activation of IL-4RC, such as atopic dermatitis (AD), e.g. moderate to severe atopic dermatitis, atopic eczema, asthma, e.g. moderate to severe eosinophilic or oral steroid dependent asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), chronic rhinosinusitis without nasal polyps (CRsNP), eosinophilic esophagitis (EoE), prurigo nodularis (PN), skin infections, chronic obstructive pulmonary disease (COPD), chronic spontaneous urticaria (CSU), chronic inducible cold urticaria (CINDU), allergic fungal rhinosinusitis (AFRS).
Owner:FORMYCON AG

Anti-IL-18 antibody therapy for treatment of atopic dermatitis

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).
Owner:阿波罗AP43有限公司

Composition for treating inflammatory skin diseases

The present invention relates to a dermatological or dermatocosmetic composition in the form of a paraffin-free emulsion, which is particularly suitable for the treatment of inflammatory skin diseases, in particular sensitive or atopic skin. The composition comprises an aqueous phase comprising at least one emollient selected from polyols and an oily phase comprising an oily emollient system comprising at least 70% by weight of safflower oil and a second oily emollient.
Owner:PIERRE FABRE DERMO COSMETIQUE SA

Composition for the treatment of inflammatory skin diseases

The present invention relates to a dermatological or cosmetic skin composition in the form of a paraffin-free emulsion, particularly suitable for the treatment of inflammatory skin diseases, especially sensitive or atopic skin. The composition comprises an aqueous phase containing at least one emollient selected from polyols, and an oil phase containing an oily emollient system comprising at least 70% by weight of safflower oil and a second oily emollient.
Owner:PIERRE FABRE DERMO COSMETIQUE SA

COMPOSITION FOR THE TREATMENT OF INFLAMMATORY SKIN DISORDERS

The invention relates to a dermatological or dermo-cosmetic composition in the form of a paraffin-free emulsion, particularly suitable for the treatment of inflammatory skin disorders, especially on sensitive or atopic skin. This composition comprises an aqueous phase containing at least one emollient selected from polyols, and an oily phase containing an oily emollient system comprising safflower oil at least 70% by weight and a second oily emollient.
Owner:PIERRE FABRE DERMO COSMETIQUE SA

Composition for preventing, alleviating, or treating atopic dermatitis, containing extract of scutellaria baicalensis and raphanus sativus l. seeds as active ingredient

PCT designated stage expiredWO2025023507A1AntipyreticAnalgesicsCytotoxicityAcropustulosis
The present invention relates to a composition for preventing, alleviating, or treating atopic dermatitis, containing an extract of Scutellaria baicalensis and Raphanus sativus L. seeds as an active ingredient. Specifically, a Scutellaria baicalensis extract and a Raphanus sativus L. seed extract exhibit cytotoxicity or have no significant difference in NO production inhibitory effects, whereas the extract of Scutellaria baicalensis and Raphanus sativus L. seeds of the present invention, extracted after mixing at a weight ratio of 2-4:8-6, significantly inhibits LPS-induced NO production without cytotoxicity, reduces the thickness of atopic dermatitis-induced skin in an animal model, has a skin moisturizing effect, and significantly reduces the production of atopic dermatitis-related factors of IgE and IL-4, and thus the present invention can be usefully used in health functional foods, medicines and the like for preventing, alleviating, or treating atopic dermatitis.
Owner:KOREA INST OF ORIENTAL MEDICINE

Treatment of skin condition

To provide a pharmaceutical composition for use in a method of treating a skin condition.SOLUTION: Provided is a pharmaceutical composition for use in a method of treating a skin condition of a subject. The method comprises administering intradermally to the subject a botulinum neurotoxin: herein, following administration, the botulinum neurotoxin induces secretion of one or more sebaceous lipid(s) selected from a squalene, a fatty acid, a cholesterol, and a wax ester to an epidermal layer of skin; and the skin condition is selected from a group consisting of xerosis, dehydrated, dry or cracked skin, eczema, atopic eczema, type 2 Gaucher disease, Sjogren-Larsson syndrome, ichthyosis, lamellar ichthyosis, X-linked ichthyosis, bullous ichthyosiform erythroderma, essential FFA deficiency, aged dry skin, anhidrotic ectodermal dysplasia, Netherton syndrome, actinic keratosis, carbuncle, cellulitis, skin cancer, and lichen pilaris.SELECTED DRAWING: Figure 3
Owner:IPSEN BIOPHARM LTD

Compound essential oil for improving atopic dermatitis as well as preparation method and application of compound essential oil

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to compound essential oil for improving atopic dermatitis and a preparation method and application thereof. The compound essential oil comprises the following components in parts by mass: 1-5 parts of peppermint essential oil and 1-5 parts of eupatorium essential oil. The composition provided by the invention is applied to in-vivo efficacy verification in an atopic dermatitis mouse model, and the result shows that the compound essential oil has the effect of improving atopic dermatitis. The compound essential oil disclosed by the invention is safe and easily available in components, simple in preparation process, low in cost and good in curative effect, and can be used as a safe and effective external preparation for treating atopic dermatitis.
Owner:CHINA PHARM UNIV

Method for attenuating the atopic march by administering an IL-4 / IL-13 antagonist

PendingJP2025501239AOrganic active ingredientsAntibody ingredientsDiseaseAllergic condition
Methods are provided for preventing the onset of a new allergic condition or the worsening of an existing concomitant allergic condition in a subject with an atopic disease, such as atopic dermatitis, in one embodiment, the method comprises administering to the subject a course of therapy of an IL-4 / IL-13 antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.
Owner:REGENERON PHARMACEUTICALS INC

N1-(3,4-dichlorophenyl)maleamide derivatives and the use thereof in the treatment of inflammatory disorders

PCT designated stageWO2025213277A1Organic chemistryRespiratory disorderDrug allergyAllergic asthma
Provided herein are compounds of Formula I which are thymic stromal lymphopoietin (TSLP) or thymic stromal lymphopoietin receptor (TSLPR) inhibitory compounds, capable of disrupting the protein-protein interaction between TSLP and TSLPR. Compounds of Formula I and compositions thereof modulate activity or inhibit TSLP and TSLPR binding, and are useful for downregulating atopy-relevant pro-inflammatory cytokines. In particular, compounds of Formula I as described herein are useful in the treatment of skin disease, allergic asthma, allergic rhinitis, drug allergies, and food allergies. Furthermore, the compounds described herein are absorbed by the skin. (I)
Owner:THE UNIV OF BRITISH COLUMBIA +1

Anti-il-18 antibody therapy for treating atopic dermatitis

The invention relates to interleukin 18 (IL-18) antibody therapy, and to low dosage formulations of an anti-IL-18 neutralizing antibody, and their use in treating IL-18-associated diseases via sub-cutaneous delivery. The invention further relates to the use of the low dose formulations of the anti-IL-18 neutralizing antibody for treating Still's diseases, such as adult-onset Still's disease (AOSD) or the juvenile-onset form know as systemic-onset juvenile idiopathic arthritis (SoJIA)), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease, such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).
Owner:APOLLO AP43 LTD

System for providing precise personal atopic dermatitis care service

A system for providing an atopic dermatitis care service, according to an embodiment of the present invention, comprises: a skin information reception unit configured to receive, from a camera, an affected skin area image of a user; an atopic dermatitis type determination unit configured to determine, on the basis of the affected skin area image, an atopic dermatitis lesion type for the affected skin area image by using a first artificial intelligence model; an atopic dermatitis severity determination unit configured to determine, on the basis of the affected skin area image, the severity of atopic dermatitis for the affected skin area image by using a second artificial intelligence model; and a display screen generation unit configured to generate, on the basis of the atopic dermatitis lesion type for the affected skin area image and the severity of atopic dermatitis for the affected skin area image, information on an analysis result screen that is displayed on a display of a user terminal.
Owner:WOODANG NETWORK INC

A composition for relieving atopic dermatitis, its preparation method and application.

This invention provides a composition for relieving atopic dermatitis, its preparation method, and its application, belonging to the field of pharmaceutical technology. The composition comprises hydroxyphenylpropionamide benzoic acid, asiaticoside, dipotassium glycyrrhizate, and tetrahydromethylpyrimidine carboxylic acid in a mass ratio of 0.8~1.0:1.3~1.7:2.8~3.2:4.8~5.2. The components of the composition work synergistically to achieve emergency skin repair by combating skin allergies and inflammation and repairing the skin barrier. The composition can be formulated into a topical cream to improve dryness, sensitivity, itching, and barrier damage associated with atopic dermatitis. The composition and its products are free of corticosteroids, mild in nature, and suitable for daily care of sensitive and atopic skin.
Owner:PROYA COSMETICS CO LTD +1

New cosmetic or dermatological use of Gentiana crassicaulis extract

The present invention relates to the novel cosmetic use of Gentiana crassicaulis extract and / or a composition containing the same for the cosmetic treatment and / or cosmetic care of healthy skin and / or mucous membranes selected from sensitive, and / or sensitized, and / or vulnerable, and / or fragile, and / or dry, and / or atopic-prone skin and / or mucous membranes, in particular for preventing and / or reducing one or more of the unaesthetic, and / or unpleasant, and / or uncomfortable signs of healthy skin and / or mucous membranes, in particular for calming healthy skin and / or mucous membranes, and / or increasing and / or maintaining the comfort of healthy skin and / or mucous membranes, and / or reducing and / or preventing its hypersensitivity, and / or increasing and / or maintaining its moisturization, in particular for improving and / or maintaining the skin and / or mucous membrane barrier of healthy skin and / or mucous membranes. The present invention also relates to the novel use of Gentiana crassicaulis extract and / or a composition containing the same for the dermatological treatment of skin and / or mucous membranes with a damaged skin and / or mucous membrane barrier.
Owner:BASF BEAUTY CARE SOLUTIONS FRANCE SAS

Momelotinb (CYT387) ointment for treating atopic dermatitis

The invention discloses an application of a Momelotinb (CYT387) ointment in preparation of a medicine for treating atopic dermatitis and a preparation method of the Momelotinb (CYT387) ointment. The appearance, the viscosity, the irritation, the stability and the like of the Momelotinb (CYT387) ointment prepared by the preparation method disclosed by the invention can meet the requirements of applying on skin; the Momelotinb (CYT387) ointment has the advantages that the Momelotinb (CYT387) ointment is more easily percutaneously permeated into epidermis and dermis tissues in pharmacodynamic property, and main effective components are distributed on the superficial layer of skin, so that the Momelotinb (CYT387) ointment can be favorably applied to treatment of Compared with commercially available tacrolimus, the drug effect of the Momelotinb (CYT387) ointment is similar, however, the Momelotinb (CYT387) ointment has stronger tolerance, and compared with other hormone ointment, the Momelotinb (CYT387) ointment is accurate in target spot and more remarkable in curative effect on AD (Alzheimer's disease). Clinically developed as a substitute medicine of tacrolimus or other hormones for treating atopic dermatitis, the compound has great practical application value, and can be used as a novel and effective external preparation for treating atopic dermatitis.
Owner:金文玉

Cosmetic composition for improving skin itching and atopy, cosmetics comprising same, and method for preparing same

A cosmetic composition for alleviating skin itching and improving atopic symptoms, according to the present invention, comprises a eutectic mixture of glutamine and linoleic acid, and exhibits the following effects: increasing the skin penetration of glutamine and enhancing skin barrier function, thereby substantially alleviating atopic symptoms including itching; improving the water solubility of linoleic acid, thereby enhancing antioxidant activity and skin protection effects; providing synergistically enhanced effects on alleviating atopic symptoms including itching and enhancing skin protection, as compared to the use of glutamine or linoleic acid alone, without adverse effects; and achieving enhanced effects in alleviating atopic symptoms including itching and improving skin protection, without adverse effects associated with surfactants and oils.
Owner:SEORIN CO CO LTD

Skin whitening, Anti-bacterial or Anti-atopic composition, containing syzygium formosum extract as active ingredient

Proposed is a composition for skin whitening, including a Syzygium formosum extract as an active ingredient. The Syzygium formosum extract has excellent tyrosinase inhibitory activity, and thus can be usefully used as a cosmetic composition for skin whitening or a composition for preventing or alleviating melanin hyperpigmentation diseases. In addition, the Syzygium formosum extract has excellent antibacterial and antiatopic activities, thereby being useful as an antibacterial and antiatopic composition.
Owner:CARBOEXPERT INC

Maqui berry extracts for treatment of skin diseases

To provide maqui berry for use in the treatment or prevention of skin diseases, wherein maqui berry may be the primary natural active ingredient.SOLUTION: Particular embodiments as disclosed herein find application in, inter alia, the prophylaxis and the treatment of skin diseases, in particular, dermatitis, atopic dermatitis (neurodermatitis), dermatitis solaris, eczema, hand eczema, lichen planus, lupus erythematosus, psoriasis, urticaria, itching, scabies, pigmentation, freckles, and dry / atopic skin of humans. In particular, the present invention relates to the use of maqui berry extract in the manufacture of a medicament or dietary supplement for use in treating or preventing the skin diseases or defects.SELECTED DRAWING: Figure 1
Owner:ANKLAM EXTRAKT GMBH

Lactobacillus paracasei ATG-EI strain or composition comprising same for preventing or treating respiratory disease

ActiveUS12667598B2DiseaseWhite blood cell
A novel strain, Lactobacillus paracasei ATG-E1 (Accession No. KCTC 14245BP), and a composition containing the same for preventing or treating respiratory diseases which are caused by fine particulate matter. The Lactobacillus paracasei ATG-E1 strain reduces the number of immune cells bronchoalveolar and lung tissues and inhibits the expression of inflammatory cytokines such as interleukin-17A (IL-17A), tumor necrosis factor-α (TNF-α), macrophage inflammatory protein 2 (MIP2), C-X-C motif chemokine ligand 1 (CXCL-1), macrophage inflammatory protein-α (MIP-1α) or interleukin-6 (IL-6). Therefore, the Lactobacillus paracasei ATG-E1 strain can be used for a treatment or health functional food for various respiratory diseases such as acute and chronic bronchitis, catarrhal bronchitis, bronchitis obliterans, inflammatory bronchitis, bronchial asthma, atopic asthma, non-atopic asthma, atopic IgE-mediated asthma, allergic asthma, non-allergic asthma, chronic bronchoconstriction, acute bronchoconstriction, chronic obstructive pulmonary disease, bronchial adenoma, pulmonary tuberculosis, emphysema, lung abscess, pulmonary fibrosis, lung cancer, airway cancer, bronchoalveolar cancer, and bronchial cancer.
Owner:ATOGEN CO LTD +1